BioSpace News Archive

Disease education programaims to help patients, caregivers and families affectedby Fabry disease to make informed healthcare decisions

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the initiation and enrollment of the first patients in its planned supplemental open-label safety study evaluating ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced the addition of Peter Nielsen, Ph.D. to its scientific advisory board.

The demand within the global market for saline laxatives has been rising on account of key advancements in the pharmaceutical industry across the world.

Cigna’s International Markets business published the third edition of its COVID-19 Global Impact Study, which sheds new light on the impact of the virus on global perceptions of health and well-being.

The global outpatient home therapy market is gaining traction owing to the convenience it provides to patients.

Current research directions in the upper limb prosthetics market hover around improving the performance outcomes so that the devices meet the functional requirements in amputees.

Transparency Market Research has published a new report titled, ‘Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Hemorrhagic shock is a life-threatening condition of reduced tissue perfusion, resulting in the inadequate delivery of oxygen and nutrients that are necessary for cellular function.

The drive for clinical procedures and devices in the management of gastroesophageal reflux disease stemmed from the wide prevalence of the condition.